Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
[HTML][HTML] Inflammasome activation in infected macrophages drives COVID-19 pathology
Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine
production, viral RNA and a sustained interferon (IFN) response, all of which are …
production, viral RNA and a sustained interferon (IFN) response, all of which are …
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Microfluidic bioprinting of tough hydrogel-based vascular conduits for functional blood vessels
Three-dimensional (3D) bioprinting of vascular tissues that are mechanically and
functionally comparable to their native counterparts is an unmet challenge. Here, we …
functionally comparable to their native counterparts is an unmet challenge. Here, we …
Evasion of type I interferon by SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication and host
immune response determine coronavirus disease 2019 (COVID-19), but studies evaluating …
immune response determine coronavirus disease 2019 (COVID-19), but studies evaluating …
SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration
SARS-CoV-2 has been reported to show a capacity for invading the brains of humans and
model animals. However, it remains unclear whether and how SARS-CoV-2 crosses the …
model animals. However, it remains unclear whether and how SARS-CoV-2 crosses the …
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
The SARS-CoV-2 virus has infected more than 261 million people and has led to more than
5 million deaths in the past year and a half (https://www. who. org/). Individuals with SARS …
5 million deaths in the past year and a half (https://www. who. org/). Individuals with SARS …
Two years into the COVID-19 pandemic: lessons learned
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
The SARS‐CoV‐2 coronavirus encodes an essential papain‐like protease domain as part of
its non‐structural protein (nsp)‐3, namely SARS2 PLpro, that cleaves the viral polyprotein …
its non‐structural protein (nsp)‐3, namely SARS2 PLpro, that cleaves the viral polyprotein …